Stephanie Booy1, Casper Hj van Eijck2, Joseph Amjl Janssen3, Fadime Dogan3, Peter M van Koetsveld3, Leo J Hofland3. 1. Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center Rotterdam, The Netherlands ; Department of Surgery, Erasmus Medical Center Rotterdam, The Netherlands. 2. Department of Surgery, Erasmus Medical Center Rotterdam, The Netherlands. 3. Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center Rotterdam, The Netherlands.
Abstract
INTRODUCTION: Pancreatic cancer is a highly aggressive malignancy with few treatment options. The overexpression of several growth factors, including insulin and insulin-like growth factors (IGFs), can underlie the aggressive nature of this disease. Previous research has demonstrated potent effects of interferon (IFN)-β on pancreatic cancer cell growth, however up till now it is unknown whether IFN-β is able to counteract IGF1, IGF2 and insulin-induced pancreatic cancer cell proliferation and migration. METHODS: Expression of IGF- and insulin receptors was determined and the stimulatory effects of IGF1, IGF2 and insulin on cell proliferation and migration, as well as the inhibitory effects of IFN-β were evaluated in 3 human pancreatic adenocarcinoma cell lines. RESULTS: Both the insulin- and the IGF1 receptor were variably expressed in the cell lines. IGF1, IGF2 and insulin were capable of stimulating cell proliferation in all three cell lines, however cell migration was significantly enhanced only in the BxPC-3 cell line. IFN-β significantly inhibited IGF1-, IGF2- and insulin-stimulated proliferation in all three cell lines in a dose and time dependent manner. Furthermore, in the BxPC-3 cell line IFN-β significantly inhibited both basal and IGF1-, IGF2- and insulin-stimulated cell migration. CONCLUSION: Both IGF1, -2 and insulin were capable of stimulating proliferation and migration in human pancreatic cancer cells irrespective of the type of receptor expressed. This study demonstrates that insulin, in addition to IGF1 and IGF2, may play an important role in the progression of pancreatic cancer. Moreover, IFN-β strongly inhibits growth factor stimulated cell proliferation and migration. Our study supports previous findings which have suggested that IFN-β can be a potential promising anti-cancer agent in pancreatic cancer.
INTRODUCTION:Pancreatic cancer is a highly aggressive malignancy with few treatment options. The overexpression of several growth factors, including insulin and insulin-like growth factors (IGFs), can underlie the aggressive nature of this disease. Previous research has demonstrated potent effects of interferon (IFN)-β on pancreatic cancer cell growth, however up till now it is unknown whether IFN-β is able to counteract IGF1, IGF2 and insulin-induced pancreatic cancer cell proliferation and migration. METHODS: Expression of IGF- and insulin receptors was determined and the stimulatory effects of IGF1, IGF2 and insulin on cell proliferation and migration, as well as the inhibitory effects of IFN-β were evaluated in 3 humanpancreatic adenocarcinoma cell lines. RESULTS: Both the insulin- and the IGF1 receptor were variably expressed in the cell lines. IGF1, IGF2 and insulin were capable of stimulating cell proliferation in all three cell lines, however cell migration was significantly enhanced only in the BxPC-3 cell line. IFN-β significantly inhibited IGF1-, IGF2- and insulin-stimulated proliferation in all three cell lines in a dose and time dependent manner. Furthermore, in the BxPC-3 cell line IFN-β significantly inhibited both basal and IGF1-, IGF2- and insulin-stimulated cell migration. CONCLUSION: Both IGF1, -2 and insulin were capable of stimulating proliferation and migration in humanpancreatic cancer cells irrespective of the type of receptor expressed. This study demonstrates that insulin, in addition to IGF1 and IGF2, may play an important role in the progression of pancreatic cancer. Moreover, IFN-β strongly inhibits growth factor stimulated cell proliferation and migration. Our study supports previous findings which have suggested that IFN-β can be a potential promising anti-cancer agent in pancreatic cancer.
Authors: Elizabeth Buck; Prafulla C Gokhale; Susan Koujak; Eric Brown; Alexandra Eyzaguirre; Nianjun Tao; Maryland Rosenfeld-Franklin; Lorena Lerner; M Isabel Chiu; Robert Wild; David Epstein; Jonathan A Pachter; Mark R Miglarese Journal: Mol Cancer Ther Date: 2010-10-05 Impact factor: 6.261
Authors: Mark J Mulvihill; Andrew Cooke; Maryland Rosenfeld-Franklin; Elizabeth Buck; Ken Foreman; Darla Landfair; Matthew O'Connor; Caroline Pirritt; Yingchaun Sun; Yan Yao; Lee D Arnold; Neil W Gibson; Qun-Sheng Ji Journal: Future Med Chem Date: 2009-09 Impact factor: 3.808
Authors: Peter M van Koetsveld; Giovanni Vitale; Wouter W de Herder; Richard A Feelders; Katy van der Wansem; Marlijn Waaijers; Casper H J van Eijck; Ernst-Jan M Speel; Ed Croze; Aart-Jan van der Lely; Steven W J Lamberts; Leo J Hofland Journal: J Clin Endocrinol Metab Date: 2006-08-15 Impact factor: 5.958
Authors: Giovanni Vitale; Peter M van Koetsveld; Wouter W de Herder; Katy van der Wansem; Joop A M J L Janssen; Annamaria Colao; Gaetano Lombardi; Steven W J Lamberts; Leo J Hofland Journal: Am J Physiol Endocrinol Metab Date: 2009-01-13 Impact factor: 4.310
Authors: M Caraglia; M Marra; P Tagliaferri; S W J Lamberts; S Zappavigna; G Misso; F Cavagnini; G Facchini; A Abbruzzese; L J Hofland; G Vitale Journal: Curr Cancer Drug Targets Date: 2009-08-01 Impact factor: 3.428
Authors: Stephanie Booy; Casper H J van Eijck; Fadime Dogan; Peter M van Koetsveld; Leo J Hofland Journal: J Cell Mol Med Date: 2014-01-25 Impact factor: 5.310